“Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s71. doi:10.25251/skin.6.supp.71.